CD19 and B-cell non-Hodgkin lymphoma: Level of CD19 expression is not currently used as a decision tool for anti‐CD19 therapy since CD19 expression is highly conserved, with normal to high levels of expression maintained on nearly 90% of B‐cell lymphomas.22